Last 12 months
Inside the activity.
0 purchase rows · 214 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 14 |
| Dec 2025 | 0 | 10 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 26 |
| Apr 2026 | 0 | 14 |
| May 2026 | 0 | 28 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 36 |
| Aug 2026 | 0 | 44 |
| Sep 2026 | 0 | 15 |
| Oct 2026 | 0 | 6 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2021 Filed May 14, 2021 20:27 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,547 | $50.51 | $78,135.88 |
DisclosureSEC source: 0001447362-21-000118 · wf-form4_162102401970974.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,919 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $50.285 to $51.215, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 13, 2021 Filed May 14, 2021 20:27 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 886 | $49.75 | $44,076.73 |
DisclosureSEC source: 0001447362-21-000118 · wf-form4_162102401970974.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,466 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $49.260 to $50.250, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:33 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 800 | $52.88 | $42,300.80 |
DisclosureSEC source: 0001447362-21-000116 · wf-form4_162093800831488.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 559,352 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $52.570 to $53.350, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:33 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 2,533 | $51.94 | $131,551.36 |
DisclosureSEC source: 0001447362-21-000116 · wf-form4_162093800831488.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,152 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $51.570 to $52.460, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:33 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 697 | $54.40 | $37,919.59 |
DisclosureSEC source: 0001447362-21-000116 · wf-form4_162093800831488.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 562,685 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $54.240 to $54.540, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:33 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,100 | $53.69 | $59,053.50 |
DisclosureSEC source: 0001447362-21-000116 · wf-form4_162093800831488.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 563,382 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $53.210 to $54.180, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:33 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,157 | $52.60 | $60,861.67 |
DisclosureSEC source: 0001447362-21-000116 · wf-form4_162093800831488.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564,482 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $52.185 to $53.180, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:33 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 379 | $51.63 | $19,567.01 |
DisclosureSEC source: 0001447362-21-000116 · wf-form4_162093800831488.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565,639 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $51.110 to $52.070, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:14 UTC |
Olson TiffanyDirector
|
GrantRestricted Stock Units · Derivative | 1,460 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-21-000112 · wf-form4_162085048170377.xml · derivative · entry 2 Olson Tiffany · CIK 0001442172 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,460 Underlying: Common Stock · 1,460 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on May 10, 2022. F3 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on May 10, 2022. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:14 UTC |
Olson TiffanyDirector
|
GrantStock option (right to buy) · Derivative | 5,936 | $0.00 Strike: $54.78 | $0.00 |
DisclosureSEC source: 0001447362-21-000112 · wf-form4_162085048170377.xml · derivative · entry 1 Olson Tiffany · CIK 0001442172 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,936 Underlying: Common Stock · 5,936 shares Expires 2031-05-09 F1 · derivative.exercise_date: One-third of the shares shall vest on May 10, 2022, and the remaining shares shall vest in 24 equal monthly installments thereafter. Read SEC document |
| April 28, 2021 Filed Apr 29, 2021 20:14 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 2,442 | $69.37 | $169,406.42 |
DisclosureSEC source: 0001447362-21-000101 · wf-form4_161972726245517.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,018 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $69.090 to $69.810, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 28, 2021 Filed Apr 29, 2021 20:14 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 8,166 | $68.72 | $561,167.52 |
DisclosureSEC source: 0001447362-21-000101 · wf-form4_161972726245517.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,460 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $68.085 to $69.075, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 28, 2021 Filed Apr 29, 2021 20:14 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 3,766 | $67.38 | $253,738.02 |
DisclosureSEC source: 0001447362-21-000101 · wf-form4_161972726245517.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576,626 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $67.040 to $68.035, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 20:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 2,904 | $71.35 | $207,185.88 |
DisclosureSEC source: 0001447362-21-000099 · wf-form4_161964101666972.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,392 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $71.050 to $71.690, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 20:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 11,470 | $70.76 | $811,594.26 |
DisclosureSEC source: 0001447362-21-000099 · wf-form4_161964101666972.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583,296 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $70.050 to $71.030, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 20:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 5,782 | $70.06 | $405,098.48 |
DisclosureSEC source: 0001447362-21-000099 · wf-form4_161964101666972.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,766 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $69.850 to $70.300, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 20:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,993 | $69.30 | $138,118.89 |
DisclosureSEC source: 0001447362-21-000099 · wf-form4_161964101666972.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,548 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $68.845 to $69.650, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 20:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 6,599 | $68.34 | $450,982.26 |
DisclosureSEC source: 0001447362-21-000099 · wf-form4_161964101666972.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602,541 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $67.840 to $68.770, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 22, 2021 Filed Apr 23, 2021 20:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,769 | $65.55 | $181,507.95 |
DisclosureSEC source: 0001447362-21-000093 · wf-form4_161920850708574.xml · nonDerivative · entry 8 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 290,993 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F10 · price: This transaction was executed in multiple trades at prices ranging from $65.310 to $65.780, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| April 22, 2021 Filed Apr 23, 2021 20:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 3,431 | $64.82 | $222,411.14 |
DisclosureSEC source: 0001447362-21-000093 · wf-form4_161920850708574.xml · nonDerivative · entry 7 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 293,762 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $64.310 to $65.300, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| April 22, 2021 Filed Apr 23, 2021 20:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,300 | $63.65 | $82,738.50 |
DisclosureSEC source: 0001447362-21-000093 · wf-form4_161920850708574.xml · nonDerivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 297,193 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $63.260 to $64.230, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,550 | $63.26 | $98,046.80 |
DisclosureSEC source: 0001447362-21-000093 · wf-form4_161920850708574.xml · nonDerivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 298,493 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $63.170 to $63.410, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 3,970 | $62.78 | $249,252.48 |
DisclosureSEC source: 0001447362-21-000093 · wf-form4_161920850708574.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 300,043 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $62.170 to $63.150, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,480 | $61.77 | $91,413.68 |
DisclosureSEC source: 0001447362-21-000093 · wf-form4_161920850708574.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 304,013 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $61.110 to $62.100, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 300 | $60.28 | $18,084.90 |
DisclosureSEC source: 0001447362-21-000093 · wf-form4_161920850708574.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 305,493 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $59.860 to $60.495, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 200 | $59.20 | $11,839.00 |
DisclosureSEC source: 0001447362-21-000093 · wf-form4_161920850708574.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 305,793 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $58.770 to $59.620, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:07 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 500 | $69.63 | $34,815.00 |
DisclosureSEC source: 0001447362-21-000091 · wf-form4_161886281589883.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,140 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $69.36 to $69.80, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:07 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 6,019 | $68.74 | $413,746.06 |
DisclosureSEC source: 0001447362-21-000091 · wf-form4_161886281589883.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,640 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $68.33 to $69.31, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:07 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 7,855 | $68.02 | $534,297.10 |
DisclosureSEC source: 0001447362-21-000091 · wf-form4_161886281589883.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,659 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $67.33 to $68.32, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 20:10 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 308 | $71.69 | $22,078.98 |
DisclosureSEC source: 0001447362-21-000077 · wf-form4_161851738006629.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,514 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $71.680 to $71.690, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 20:10 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 4,100 | $71.19 | $291,862.60 |
DisclosureSEC source: 0001447362-21-000077 · wf-form4_161851738006629.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,822 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $70.670 to $71.650, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 20:10 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 6,970 | $70.20 | $489,280.06 |
DisclosureSEC source: 0001447362-21-000077 · wf-form4_161851738006629.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 627,922 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $69.640 to $70.600, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 20:10 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 2,996 | $68.82 | $206,187.72 |
DisclosureSEC source: 0001447362-21-000077 · wf-form4_161851738006629.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634,892 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $68.470 to $69.410, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:10 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,200 | $69.41 | $83,296.80 |
DisclosureSEC source: 0001447362-21-000077 · wf-form4_161851738006629.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637,888 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $69.190 to $69.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:10 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 6,302 | $68.51 | $431,731.11 |
DisclosureSEC source: 0001447362-21-000077 · wf-form4_161851738006629.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 639,088 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $68.190 to $69.080, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:10 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 3,611 | $67.69 | $244,421.37 |
DisclosureSEC source: 0001447362-21-000077 · wf-form4_161851738006629.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 645,390 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $67.145 to $68.120, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:10 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 3,261 | $66.58 | $217,130.42 |
DisclosureSEC source: 0001447362-21-000077 · wf-form4_161851738006629.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,001 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $66.140 to $67.060, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 20:49 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 849 | $73.71 | $62,577.24 |
DisclosureSEC source: 0001447362-21-000072 · wf-form4_161791493268728.xml · nonDerivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 305,993 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $73.340 to $74.060, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 20:49 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,757 | $72.92 | $128,125.71 |
DisclosureSEC source: 0001447362-21-000072 · wf-form4_161791493268728.xml · nonDerivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 306,842 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $72.285 to $73.250, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 20:49 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,394 | $71.66 | $99,889.86 |
DisclosureSEC source: 0001447362-21-000072 · wf-form4_161791493268728.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 308,599 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $71.270 to $72.230, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 20:49 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 3,500 | $70.62 | $247,184.00 |
DisclosureSEC source: 0001447362-21-000072 · wf-form4_161791493268728.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 309,993 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $70.180 to $71.065, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 22:15 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 40,000 | $73.99 | $2,959,708.00 |
DisclosureSEC source: 0001447362-21-000070 · wf-form4_161783372923988.xml · nonDerivative · entry 3 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 533,577 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $73.4821 to $74.1945, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:49 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 5,590 | $74.06 | $413,967.45 |
DisclosureSEC source: 0001447362-21-000072 · wf-form4_161791493268728.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 313,493 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $73.800 to $74.510, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:49 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,910 | $73.54 | $140,469.04 |
DisclosureSEC source: 0001447362-21-000072 · wf-form4_161791493268728.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 319,083 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $72.790 to $73.780, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 22:15 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 20,000 | $73.22 | $1,464,422.00 |
DisclosureSEC source: 0001447362-21-000070 · wf-form4_161783372923988.xml · nonDerivative · entry 2 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 573,577 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $73.1857 to $73.2564, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 22:15 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 50,000 | $71.79 | $3,589,600.00 |
DisclosureSEC source: 0001447362-21-000070 · wf-form4_161783372923988.xml · nonDerivative · entry 1 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 593,577 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.1820 to $72.1647, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:05 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 20,000 | $70.80 | $1,416,034.00 |
DisclosureSEC source: 0001447362-21-000067 · wf-form4_161740106185755.xml · nonDerivative · entry 4 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 643,577 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $70.5502 to $71.0532, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:05 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 40,000 | $70.00 | $2,800,052.00 |
DisclosureSEC source: 0001447362-21-000067 · wf-form4_161740106185755.xml · nonDerivative · entry 3 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 663,577 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $69.3558 to $70.3535, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 22:05 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 10,000 | $68.15 | $681,545.00 |
DisclosureSEC source: 0001447362-21-000067 · wf-form4_161740106185755.xml · nonDerivative · entry 2 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 703,577 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 22:05 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 20,000 | $67.56 | $1,351,252.00 |
DisclosureSEC source: 0001447362-21-000067 · wf-form4_161740106185755.xml · nonDerivative · entry 1 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 713,577 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $67.0821 to $68.0430, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.